Next-Generation (R & D) Biologics market is worth $12. 17bn in 2018 & projections of revenue until 2024

Market Research Report & Industry Analysis Reports (PRNewsFoto/RnRMarketResearch)jwplayer.key="2kY/GKwZ2uQZmDlQ9VYArfZt2b4+KhHX3+DM4zisgtE=";DALLAS, June 11, 2014 /PRNewswire-iReach /-Next-generation biologics will address shortcomings in current therapies, including inconvenient dosing and concerns over side effects.) Developmental trends include sustained release, for less-frequent dosing, and reformulations for oral and topical administration. This study predicts the next-generation biologics market will reach $12 17bn worldwide in 2018, and then multiply in revenues to 2024.

Emerging biological drugs - discover R & D, business analysis, and revenue forecasts

What's the future of biologics, especially new drug classes? Now get the latest technological and commercial analysis. Staying ahead in data and knowledge, you benefit your authority. And you explore trends, developments, results, opportunities, and sales predictions.

So vision gain's new report shows you what's possible for biological drugs - their next phase. Avoid missing out there. Instead find progress in that industry and market, discovering expected progress and revenues. See how you can gain now.

New biotechnological medicines will benefit patients and pharmaceutical companies. Read on to explore those therapies, hearing how high revenues can go.

Leading Companies in next-generation biologics market are:Roche, Eli Lilly, Novo Nordisk, Sanofi, Pfizer, Kyowa Hakko Kirin, Baxter International.

Order to purchase copy @ http://www.rnrmarketresearch.com/contacts/purchase?rname=185532.

Forecasting and other information showing the most lucrative possibilities for treatments that study gives you sales forecasts to 2024 en overall submarket, product, world, and national level. See what the future holds, assessing gains for developers and producers. Many opportunities exist. And besides giving revenue predictions, that new analysis shows recent results, growth rates, and market shares. There you discover 94 tables, 55 charts, and two interviews with authorities in the biopharmaceuticals sector. And the following sections explain what our new investigation gives you.

Analyses exclusive to that study, showing the most important commercial potentials
Discover what's really going on. Our forecasting system goes to the core of the biopharmaceutical industry's sales potential like no other work, giving revenue predictions and their meanings. That analysis benefits plans, decisions, and influence by medical interpreting your needs, R & D, and companies' abilities.

Prospects for the world market and submarkets - what's possible for pharma biotechnology?
In report, discover overall world sales to 2024 for biologics and new therapies, with discussions.

Individual revenue predictions to 2024 for 17 next-generation biologic submarkets at world level:

Regenerative medicine, with submarket breakdowns for tissue engineering, stem cells, and gene therapies Antibodies, including monoclonal antibodies (mAbs), with sub-forecasting for antibody-drug conjugates (ADCs), engineered bispecific Antibody agents fragments and antibody-like protein (ALP) platforms Biosimilars (follow-on protein products).And discover other segments' forecasts to 2024:

Insulins, with submarkets for ultra-long acting, oral, and ultra-rapid-acting insulins Growth hormones Recombinant coagulation factors Other types of next-stage therapeutic proteins.Product forecasts for new forms, variations, and use of biological therapy
how will individual drugs perform to 2024 at world level? This report predicts revenues of seven top brands & those seven therapies will earn combined revenue of more than $10bn in 2024:

Adcetris Kadcyla Gazyva Tresiba Afrezza Plegridy EloctateGet complete report details @ http://www.rnrmarketresearch.com/next-generation-biologics-rd-industry-and-market-2014-2024-market-report.html.

The report explains trends, processes, and events affecting the biopharma industry and market from 2014, including these forces:

Limitations of existing biologics Promise of next-generation biologics, and product launches Extension of half-life series - pegylation and other technologies Demand rising for biological therapies Contract manufacturers (CMOs) serving those developmental needs and trends.And you explore these influences, among others:

Disease incidence affecting demand for those more-developed medicines Improvements in therapeutic antibodies, including targeted cytotoxic therapies R & D pipelines - e.g. for immunotoxins - including agents in clinical development Biosimilar insulins likely from 2015 - transformation of that market Effects of rising incidence rates in cancer, diabetes, and cardiovascular disorders.In three main ways our new investigation helps you gain recognition for insight, with data found only there:

Revenues to 2024 at world level, for 17 submarkets, and 7 products - explore outlooks for production, marketing, and sales Forecasts to 2024 for 9 national markets in North America, Europe, and Asia - assess countries for revenues and sales expansions Prospects for established competitors, companies, and new entrants rising - investigate portfolios, results, strategies, R & D, and opinions from interviews.Following companies are mentioned in this report:

3SBio, Aastrom Biosciences, AbbVie, Abcam, Ablynx, ADC Therapeutics and Adnexus (part of Bristol-Myers Squibb), Adocia, Advanced Cell Technology, Advantagene, Affibody and Agence Nationale de sécurité du Médicament et des produits de santé (ANSM), Alcon (part of Novartis)
Alexion Pharmaceuticals, Alfacell (now Tamir Biotechnology), Alkermes, Allergan, Allozyne, Ambrx, Amgen, AMRI, AnGes, Applied Genetic Technologies (AGTC), Ark Therapeutics, Astellas Pharma, AstraZeneca, Athersys, Medical Avita, Babraham Institute, Baxter International, Bayer Healthcare, Belrose Pharma, Benda Pharmaceutical, Biocad, BioCancell Therapeutics, Biocon, Biodel, Biogen Idec, Bioheart, BioMarin Pharmaceutical, Biopartners (part of Bioton), Biotest, Bioton, BioVex Group (part of Amgen), BioWa (part of Kyowa Hakko Kirin), bluebird bio, Boehringer Ingelheim, BrainStorm Cell Therapeutics, Bristol-Myers Squibb, Capricor Therapeutics, Cardio3 BioSciences, Cardium Therapeutics, Catalent Pharma Solutions, Celgene, Celladon, CellCoTec & other.

Browse more reports on Biopharmaceuticals Market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/biopharmaceuticals.

About Us:

RnRMarketResearch.com is a database of selected syndicated market reports for global and Chinese industries including but not limited to life sciences, information technology & telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials and chemicals, public sector as well as business and financial services. We provide 24/7 online and offline support to our customers. Call with your requirements or email the details on sales@rnrmarketresearch.com research.

Media Contact: Priyank Tiwari, RnRMarketResearch, + 18883915441, sales@rnrmarketresearch.com

Distributed by PR Newswire news iReach: https://ireach.prnewswire.com

SOURCE RnRMarketResearch

RELATED LINKS
http://www.rnrmarketresearch.com

reade more... Résuméabuiyad

Power-hungry audio and video analytic applications have met their match with next-generation ultra-low-power DSP from TI

Texas Instruments Logo. (PRNewsFoto/Texas Instruments Incorporated)jwplayer.key="2kY/GKwZ2uQZmDlQ9VYArfZt2b4+KhHX3+DM4zisgtE=";DALLAS, May 20, 2014 /PRNewswire/ -- Today, Texas Instruments (TI) (NASDAQ: TXN) introduces the next-generation, ultra-low-power DSP in TI's scalable TMS320C5000™ device portfolio, the TMS320C5517 (C5517). The new DSP delivers up to 200 MHz performance enabling faster processing of data with low-power consumption for demanding applications, such as audio and video, biometrics and other analytic specific applications. These applications are opening up a world of possibilities that add capabilities such as face detection, object tracking and voice recognition to a new generation of smart products. Along with the improved performance, the C5517 DSP also offers a compelling combination of low stand-by and low active power, making it the best choice for battery-powered, portable systems requiring analytics.

Scaling the C5000 DSP portfolio

With the addition of this full-featured C5517 DSP, TI now offers a scalable C5000™ device portfolio with lower performance (50/100 MHz) C5535 DSPs to mid-range (120/150 MHz) C5514/15 DSPs and now high performance with the newest C5517 DSP (200 MHz).

Features and benefits of the C5517 DSP:

Enable external sensor connectivity. The McSPI enables low-power analytics through connectivity to external sensors. It operates in master or slave modes, as well as adds to the standard SPI ports on the device to support greater serial connectivity. Connect to standard codecs such as EICs D/A, A/D and more. McBSP is a flexible serial port that allows customers to connect to standard codecs. It also enables continuous full-duplex communication and supports up to 128 channels in TDM mode. Simplify communication between processors. The Universal Host Port Interface (UHPI) is an easy way for a host processor to connect to the DSP while allowing direct access to the DSPs memories for sharing of data between elements. Build smaller hardware for space-constrained applications. Customers can pack signal processing performance into systems with challenging space and power restrictions due to the C5517 DSPs small 10x10 footprint and ultra-low power operation. Enhance and extend product lines. The C5517 DSP offers a greater number and variety of peripherals and greater signal processing performance than previous members of TI's ultra-low-power DSP family. This enables developers to add new capabilities or improve analytic performance of an existing product line, while leveraging the same tool and software basis previously used.Simplifying development with a scalable software solution

The new C5517 DSP is software compatible with previous C5000 devices, which allows existing customers to easily take advantage of the new features and 200 MHz operation. In addition to software compatibility, TI offers a complete tool chain which includes a full chip support library that customers can use to start their designs. C5517 DSP customers also have access to tips from TI's experienced partners and active TI E2E™ communities from whom they can get advice, recommendations and support for their designs. For example, one of the third-party developers, SNAP Sensor technology, helps turn TI's C5517 DSP into a machine vision solution with their specific hardware, software and vision module.

"The C5517 solution enables rapid development and customization of vision sensing applications. Working with TI allowed us to create a cost and power optimized people sensing and information extraction solution," said Pascal Nussbaum, SNAP Sensor CTO. "The SNAP Suite development environment facilitates quick and easy vision application development on a video stream powered by the C5517 DSP. This SNAP Sensor module will be available in June."

Availability and pricing

TI's C5517 EVM is available now through TI distribution partners or TI.com for $499 and includes a TPS65023 integrated power management step-down converter to manage the power. Additionally, the silicon is sampling now for $9.05/1KU.

For more information:

About Texas Instruments

Texas Instruments Incorporated (TI) is a global semiconductor design and manufacturing company that develops analog ICs and embedded processors. By employing the world's brightest minds, TI creates innovations that shape the future of technology. TI is helping more than 100,000 customers transform the future, today. Learn more at www.ti.com.

Trademarks

TMS320C5000, C5000 and TI E2E are trademarks of Texas Instruments Incorporated. All trademarks are the property of their respective owners.

SOURCE Texas Instruments

RELATED LINKS
http://www.ti.com

reade more... Résuméabuiyad